Silo Pharma, a biopharmaceutical company, has announced the initiation of a drug-device robustness study for SPC-15, a therapeutic candidate for post-traumatic stress disorder (PTSD). The study is designed to evaluate the compatibility and performance of the drug with its intended delivery device, a critical step before regulatory engagement.
The company plans to use the data from this study to support a request for a Type C meeting with the U.S. Food and Drug Administration (FDA). Type C meetings are typically used to discuss specific development issues, such as study design or manufacturing questions, and can help align the company's plans with FDA expectations.
SPC-15 is a novel formulation targeting the treatment of PTSD, a condition affecting millions worldwide. The robustness study is part of Silo Pharma's broader strategy to advance SPC-15 through the clinical pipeline. As of June 30, 2026, no further details on the study timeline or results have been released.
